Publications by authors named "Hiroshige Yoshioka"

Introduction: Extensive small cell lung cancer (ES-SCLC) are currently managed using first-line chemotherapy options, including atezolizumab (Atezo) plus etoposide and carboplatin (CE) or durvalumab (Durva) plus etoposide with either cisplatin (PE) or carboplatin (CE). However, a definitive distinction in therapeutic effects between Atezo and Durva in these regimens remains unestablished.

Methods: We analyzed data from 100 patients diagnosed with ES-SCLC who received immune checkpoint inhibitors (ICIs) as first-line chemotherapy.

View Article and Find Full Text PDF

Background: Cachexia is a poor prognostic factor in many advanced cancers. Cachexia diagnostic criteria of the European Palliative Care Research Collaboration (EPCRC) may underestimate cachexia in Asians; therefore, new criteria have been proposed by the Asian Working Group for Cachexia (AWGC). We compared both criteria to determine differences in diagnostic rates and their association with lung cancer prognosis.

View Article and Find Full Text PDF
Article Synopsis
  • EGFR-TKIs are crucial for treating advanced non-small-cell lung cancer with EGFR gene mutations, with five variants approved in Japan, including gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib.
  • Osimertinib is the only EGFR-TKI approved for second-line therapy in patients with the T790M mutation after initial treatment, making it essential to choose the right first-line therapy carefully.
  • The article presents clinical data on EGFR-TKIs for first and second-line treatments, highlights the importance of patient and mutation subtype considerations, and shares experiences from transitioning between these therapies.
View Article and Find Full Text PDF

Background: We conducted a randomize phase II study to evaluate the efficacy and safety of topoisomerase II inhibitor amrubicin plus topoisomerase I inhibitor irinotecan (AI) compared with cisplatin plus irinotecan (PI) as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer (SCLC).

Patients And Methods: Chemo-naïve patients with pathologically proven ED-SCLC (including limited disease (LD) SCLC with malignant effusion) were enrolled. Patients were randomized 1:1 to receive either AI (amrubicin 90mg/m on day 1 and irinotecan 50mg/m on days 1 and 8 of a 21-day cycle) or PI (cisplatin 60mg/m on day 1 and irinotecan 60mg/m on days 1, 8 and 15 of a 28-day cycle).

View Article and Find Full Text PDF

In patients with non-small cell lung cancer (NSCLC) who present with radiologically undetermined malignant pleural dissemination or incidental surgical diagnosis of the same, surgery is generally not the preferred option; systemic therapy is favoured. However, there is no consensus on incorporating primary site resection into the treatment plan. Retrospective analyses hint at potential benefits of combining systemic therapy with primary site resection, but prospective studies have yet to confirm these findings.

View Article and Find Full Text PDF
Article Synopsis
  • The JCOG0802/WJOG4607L trial showed segmentectomy is better than lobectomy for overall survival in small-peripheral non-small-cell lung cancer, but locoregional relapse (LR) is still a concern.
  • An analysis of 1105 patients with various tumor sites determined that factors like solid tumor appearance and close margins significantly increased the risk of LR after segmentectomy.
  • Key findings stress the importance of using thin-section CT scans and ensuring sufficient margin distance to minimize the risk of LR in patients undergoing segmentectomy.
View Article and Find Full Text PDF

Despite advancements in diagnosing and treating non-small cell lung cancer (NSCLC), the prognosis remains poor. Immune checkpoint inhibitors have shown promise in enhancing survival rates. Therefore, this study aimed to investigate the safety of nivolumab administration with concurrent chemoradiation therapy (CCRT) in patients with unresectable locally advanced NSCLC.

View Article and Find Full Text PDF

The perioperative treatments for non-small cell lung cancer (NSCLC) should control both local and microscopic systemic disease, because the survival of patients with NSCLC who underwent surgical resection alone has been dismal except in stage IA patients. One way to improve surgical outcome is the administration of chemotherapy before or after the surgical procedure. During the last two decades, many clinical studies have focused on developing optimal adjuvant or neoadjuvant cisplatin-based chemotherapy regimens that can be combined with surgical treatment and/or radiotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • Lung cancer treatment has advanced significantly in the last decade, but the cost of drugs has skyrocketed, especially in Japan where data on treatment regimens and costs is limited.
  • A survey of 60 Japanese centers revealed that a substantial number of patients with advanced lung cancer are receiving high-cost treatments, often over 500,000 Japanese yen per month, with a notable preference for immune checkpoint inhibitors (ICI).
  • The study highlights the disparity in treatment costs, showing that these high-priced therapies are widely used despite insufficient evidence for their effectiveness, urging physicians to consider treatment costs more carefully.
View Article and Find Full Text PDF
Article Synopsis
  • The Lung Cancer Surgical Study Group (LCSSG) of the Japan Clinical Oncology Group (JCOG), formed in 1986, has expanded from 26 to 52 institutions, involving various specialists in lung cancer treatment.
  • Initially focused on combined therapies, the group has shifted to studying surgical options for small-sized and peripheral non-small cell lung cancer since the 2000s, demonstrating the effectiveness of sublobar resection through clinical trials.
  • With advances in targeted therapies and the need for personalized medicine, the JCOG-LCSSG is adapting treatment strategies and conducting numerous clinical trials to enhance comprehensive care for lung cancer patients.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the risks and survival outcomes for non-small cell lung cancer (NSCLC) patients with pre-existing autoimmune disorders (AIDs) undergoing immune checkpoint blockade (ICB) therapy.
  • Conducted across 20 centers in Japan, it analyzed data from 229 patients, revealing that 25.4% experienced AID flare-ups while receiving ICB, particularly those diagnosed with NSCLC within a year of their AID diagnosis.
  • The results suggest that ICB therapy not only extends survival but also emphasizes its potential benefit for NSCLC patients with AIDs, despite some associated immune-related adverse effects.
View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the effectiveness of amivantamab plus lazertinib compared to osimertinib in treating patients with advanced non-small-cell lung cancer (NSCLC) caused by specific genetic mutations.
  • - Results showed that patients receiving the amivantamab-lazertinib treatment had a significantly longer progression-free survival (23.7 months) than those on osimertinib (16.6 months), and the response rate was similar among both groups.
  • - Side effects primarily related to treatment were noted, but the overall survival analysis indicated a potential benefit for amivantamab-lazertinib over osimertinib, with fewer serious complications leading to treatment discontinuation.
View Article and Find Full Text PDF
Article Synopsis
  • * The artemis trial is a Phase II study testing a new chemotherapy regimen combining carboplatin, paclitaxel, lenvatinib, and pembrolizumab for patients with advanced or recurrent thymic carcinoma, involving 35 participants.
  • * The main goal of the trial is to measure the objective response rate, while also assessing progression-free survival and safety of the treatment options.
View Article and Find Full Text PDF
Article Synopsis
  • Second-line immune checkpoint inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC) patients with ≤ 49% PD-L1 expression has limited effectiveness, and there is a need to understand predictors of its efficacy after platinum-based chemotherapy.
  • A study involving 54 advanced NSCLC patients in Japan found that those who did not experience disease progression after first-line chemotherapy had significantly better response rates and overall survival when treated with ICI monotherapy compared to those who had disease progression.
  • Maintaining a non-progressive disease status after chemotherapy emerged as a key independent prognostic factor for better outcomes with ICI therapy, along with a trend suggesting that a modified Glasgow Prognostic Score of 0 could correlate with longer survival.
View Article and Find Full Text PDF

Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung cancer associated with poor prognosis and resistance to conventional chemotherapy. Immune checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, were found to have clinical benefits in PSC in recent studies. Nevertheless, because these studies included a small number of patients owing to disease rarity, larger studies are needed to evaluate the effectiveness and safety of ICI-based therapy for PSC.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates factors contributing to cancer cachexia, a condition that negatively affects survival in lung cancer patients.
  • Out of 76 patients analyzed, 42 (55.2%) were found to have cachexia, with significant implications on their survival rates.
  • Key independent factors for cachexia included poor nutritional status and low levels of physical activity, suggesting that addressing these aspects could improve patient outcomes.
View Article and Find Full Text PDF

Introduction: Necitumumab plus gemcitabine and cisplatin (GCN) is a standard therapy for patients with advanced lung squamous cell carcinoma (LSqCC). However, the efficacy and tolerability of GCN in second-line or later treatment for patients previously treated with immune checkpoint inhibitors (ICIs) remain unknown.

Methods: This multicenter, retrospective, cohort study assessed the efficacy and tolerability of GCN initiated between November 1, 2019 and March 31, 2022 as second-line to fourth-line treatment in patients with advanced LSqCC who had been pretreated with ICIs.

View Article and Find Full Text PDF

Background: The factors that predict the clinical response to ramucirumab plus docetaxel (RD) after first-line chemoimmunotherapy are unresolved. We explored whether the therapeutic efficacy of prior chemoimmunotherapy could predict the outcome of RD as sequential therapy in patients with advanced non-small cell lung cancer (NSCLC).

Methods: Our study comprised 288 patients with advanced NSCLC who received RD as the second-line treatment after first-line chemoimmunotherapy at 62 Japanese institutions.

View Article and Find Full Text PDF
Article Synopsis
  • The study analyzes lymph node dissection (LND) during segmentectomy for small peripheral non-small cell lung cancer to determine the best practice for optimizing patient outcomes.
  • Among 1056 patients assessed, radiologic findings were the key factor linked to lymph node metastases (LNMs), with part-solid tumors having a significantly lower incidence of LNMs compared to pure-solid tumors.
  • The conclusions suggest selective LND is preferable for patients with pure-solid tumors, while nonadjacent interlobar and mediastinal LNDs are less impactful for those with part-solid tumors.
View Article and Find Full Text PDF
Article Synopsis
  • - Salivary gland-type tumors (SGTs) of the lung, which are rare and have a generally good prognosis, primarily include mucoepidermoid carcinoma (MEC) and adenoid cystic carcinoma (ACC), constituting over 90% of cases.
  • - Symptoms of bronchial obstruction like wheezing and shortness of breath typically lead to early diagnosis, with a reported 5-year survival rate of 63.4%.
  • - Treatment commonly involves surgical methods such as lobectomy or pneumonectomy, with lymphadenectomy recommended for patients with MEC, while advanced cases necessitate tailored therapies based on the tumor subtype.
View Article and Find Full Text PDF

Objectives: This study aimed to identify the risk factors for pulmonary functional deterioration after wedge resection for early-stage lung cancer with ground-glass opacity, which remain unclear, particularly in low-risk patients.

Methods: We analysed 237 patients who underwent wedge resection for peripheral early-stage lung cancer in JCOG0804/WJOG4507L, a phase III, single-arm confirmatory trial. The changes in forced expiratory volume in 1 s were calculated pre- and postoperatively, and a cutoff value of -10%, the previously reported reduction rate after lobectomy, was used to divide the patients into 2 groups: the severely reduced group (≤-10%) and normal group (>-10%).

View Article and Find Full Text PDF

Background: The long overall survival (OS) observed among patients with non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression in chemoimmunotherapy (CIT) groups in previous phase III trials suggests the limited efficacy of CIT among the subgroup with ≤49% PD-L1 expression on tumor cells. Hence, sequential treatment with first-line platinum-based chemotherapy followed by second-line immune checkpoint inhibitor treatment (SEQ) is an option. This study examined whether first-line CIT would provide better outcomes than SEQ in patients with advanced NSCLC with ≤49% PD-L1 expression.

View Article and Find Full Text PDF

Purpose: Effective treatments for resectable non-small-cell lung cancer (NSCLC) are limited and relapse rates are high. The interleukin (IL)-1β pathway has been linked with tumor development and progression, including in the Canakinumab Anti-Inflammatory Thrombosis Outcomes cardiovascular study in which IL-1β pathway inhibition with canakinumab reduced lung cancer incidence and mortality in an exploratory analysis.

Methods: CANOPY-A (ClinicalTrials.

View Article and Find Full Text PDF

Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as erlotinib, are standard-of-care for patients with mutation-positive non-small-cell lung cancer (NSCLC), but most patients progress within 1 year. Previously, we demonstrated that erlotinib plus bevacizumab (EB) improved progression-free survival (PFS) in patients with -positive non-squamous NSCLC in the randomized JO25567 study. To understand this effect, we conducted comprehensive exploratory biomarker analyses.

View Article and Find Full Text PDF

Background: It is shown that the postoperative adjuvant chemotherapy for non-small cell lung cancer (NSCLC) was associated with survival benefit in an elderly population. We aimed to analyze the feasibility and efficacy of alternate-day S-1, an oral fluoropyrimidine, for adjuvant chemotherapy in elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm) to IIIA (UICC TNM Classification of Malignant Tumours, 7th edition) NSCLC.

Methods: Elderly patients were randomly assigned to receive adjuvant chemotherapy for one year consisting of either alternate-day oral administration of S-1 (80 mg/m2/day) for 4 days a week (Arm A) or a daily oral administration of S-1 (80 mg/m2/day) for 14 consecutive days followed by 7-day rest (Arm B).

View Article and Find Full Text PDF